For the current week, the overall ratings of six Biotechnology stocks are worse, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
PROLOR Biotech’s (AMEX:PBTH) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). PROLOR Biotech offers treatment by using naturally occurring amino acid sequence to slow the removal of therapeutic proteins from the body without increasing toxicity or altering the overall biological activity. For Portfolio Grader’s specific subcategory of Equity, PBTH also gets an F. To get an in-depth look at PBTH, get Portfolio Grader’s complete analysis of PBTH stock.
Oncolytics Biotech (NASDAQ:ONCY) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. Oncolytics Biotech discovers and develops pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of ONCY stock.
Oncothyreon (NASDAQ:ONTY) experiences a ratings drop this week, going from last week’s D to an F. Oncothyreon is a biotechnology company that develops therapeutic approaches to cancer management. The stock gets F’s in Earnings Growth, Equity, and Cash Flow. For a full analysis of ONTY stock, visit Portfolio Grader.
The rating of Enzon Pharmaceuticals (NASDAQ:ENZN) declines this week from C to a D. Enzon Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes therapeutics to treat life-threatening diseases. For more information, get Portfolio Grader’s complete analysis of ENZN stock.
OncoGenex Pharmaceuticals (NASDAQ:OGXI) is having a tough week. The company’s rating falls from C to a D. OncoGenex Pharmaceuticals is a biopharmaceutical company that develops and commercializes new cancer therapies that address treatment resistance in cancer patients. The stock gets F’s in Earnings Growth, Equity, and Cash Flow. To get an in-depth look at OGXI, get Portfolio Grader’s complete analysis of OGXI stock.
This week, Protalix BioTherapeutics (AMEX:PLX) drops from C to a D rating. Protalix BioTherapeutics is a biotechnology company that has developed plant cell culture technology and a bioreactor system. The stock also gets an F in Equity. For a full analysis of PLX stock, visit Portfolio Grader.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.